董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Fouzia Laghrissi Thode | 女 | Independent Director | 62 | 7.01万美元 | 未持股 | 2025-12-22 |
| David Kupfer | 男 | Director | 84 | 8.40万美元 | 未持股 | 2025-12-22 |
| Inderjit Kaul | 男 | Independent Director | 69 | 未披露 | 未持股 | 2025-12-22 |
| Hans Peter Hasler | 男 | Director | 69 | 7.56万美元 | 未持股 | 2025-12-22 |
| Remy Luthringer | 男 | Chief Executive Officer and Executive Chairman of the Board | 64 | 121.00万美元 | 未持股 | 2025-12-22 |
| Jan van Heek | 男 | Director | 75 | 6.75万美元 | 未持股 | 2025-12-22 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Frederick Ahlholm | 男 | Chief Financial Officer,Secretary and SVP | 59 | 75.42万美元 | 未持股 | 2025-12-22 |
| Geoffrey Race | 男 | President | 64 | 91.97万美元 | 未持股 | 2025-12-22 |
| Remy Luthringer | 男 | Chief Executive Officer and Executive Chairman of the Board | 64 | 121.00万美元 | 未持股 | 2025-12-22 |
董事简历
中英对照 | 中文 | 英文- Fouzia Laghrissi Thode
-
Fouzia Laghrissi Thode，自2015年5月起在Minerva Neurosciences, Inc.董事会任职。Laghrissi-Thode博士曾在阿斯利康、罗氏、诺华和山德士担任过广泛治疗领域的领导职务，包括中枢神经系统、心血管、代谢疾病和生殖尿健康。自2018年4月起，Laghrissi-Thode博士担任DalCOR Pharmaceuticals的首席执行官和董事会成员。在加入DALCOR之前，Laghrissi-Thode博士曾担任阿斯利康肾脏-心脏治疗领域的美国副总裁、南旧金山站点负责人以及ZS Pharma，Inc.的首席执行官。她曾担任阿斯利康全球心血管和代谢治疗领域的副总裁。Laghrissi-Thode博士拥有法国 University of Tours School医学院的医学博士学位，获得精神病学委员会认证，曾是匹兹堡大学精神病学兼职教授。
Fouzia Laghrissi Thode has served on Board since May 2015. Dr. Laghrissi Thode has held positions of leadership at AstraZeneca, Roche and Novartis in a broad range of therapeutic areas, including central nervo system, cardiovascular, metabolic disease and genito urinary health. She is currently Chief Executive Officer and a member of the board of directors of DalCor Pharmaceuticals. Prior to joining DalCor, Dr. Laghrissi Thode served as U.S. Vice President for the renal cardio therapy area at AstraZeneca, Head of the South San Francisco site, and the chief executive officer of ZS Pharma, Inc. She was formerly vice president of the global cardiovascular and metabolism therapy area at AstraZeneca. Dr. Laghrissi Thode holds an M.D. from the University of Ts School of Medicine in France, is board certified in psychiatry and was an adjunct professor of psychiatry at the University of Pittsburgh. - Fouzia Laghrissi Thode，自2015年5月起在Minerva Neurosciences, Inc.董事会任职。Laghrissi-Thode博士曾在阿斯利康、罗氏、诺华和山德士担任过广泛治疗领域的领导职务，包括中枢神经系统、心血管、代谢疾病和生殖尿健康。自2018年4月起，Laghrissi-Thode博士担任DalCOR Pharmaceuticals的首席执行官和董事会成员。在加入DALCOR之前，Laghrissi-Thode博士曾担任阿斯利康肾脏-心脏治疗领域的美国副总裁、南旧金山站点负责人以及ZS Pharma，Inc.的首席执行官。她曾担任阿斯利康全球心血管和代谢治疗领域的副总裁。Laghrissi-Thode博士拥有法国 University of Tours School医学院的医学博士学位，获得精神病学委员会认证，曾是匹兹堡大学精神病学兼职教授。
- Fouzia Laghrissi Thode has served on Board since May 2015. Dr. Laghrissi Thode has held positions of leadership at AstraZeneca, Roche and Novartis in a broad range of therapeutic areas, including central nervo system, cardiovascular, metabolic disease and genito urinary health. She is currently Chief Executive Officer and a member of the board of directors of DalCor Pharmaceuticals. Prior to joining DalCor, Dr. Laghrissi Thode served as U.S. Vice President for the renal cardio therapy area at AstraZeneca, Head of the South San Francisco site, and the chief executive officer of ZS Pharma, Inc. She was formerly vice president of the global cardiovascular and metabolism therapy area at AstraZeneca. Dr. Laghrissi Thode holds an M.D. from the University of Ts School of Medicine in France, is board certified in psychiatry and was an adjunct professor of psychiatry at the University of Pittsburgh.
- David Kupfer
-
David Kupfer，自2015年11月起在Minerva Neurosciences, Inc.董事会任职。Kupfer博士是匹兹堡大学医学院杰出的精神病学名誉教授，在那里他担任了26年的该部门主席。他还主持了美国精神病学协会制定第五版精神障碍诊断和统计手册（“DSM-5”）的工作组，该手册确定了精神障碍的诊断和分类标准。Kupfer博士于1965年获得耶鲁大学医学博士学位。
David Kupfer has served on Board since November 2015. Dr. Kupfer is Distinguished Professor Emerit of Psychiatry at the University of Pittsburgh School of Medicine, where he chaired that department for 26 years. He also chaired the American Psychiatric Association Task Force for the development of the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders ("DSM 5"), which defines the criteria for the diagnosis and classification of mental disorders. Dr. Kupfer received his M.D. from Yale University in 1965. - David Kupfer，自2015年11月起在Minerva Neurosciences, Inc.董事会任职。Kupfer博士是匹兹堡大学医学院杰出的精神病学名誉教授，在那里他担任了26年的该部门主席。他还主持了美国精神病学协会制定第五版精神障碍诊断和统计手册（“DSM-5”）的工作组，该手册确定了精神障碍的诊断和分类标准。Kupfer博士于1965年获得耶鲁大学医学博士学位。
- David Kupfer has served on Board since November 2015. Dr. Kupfer is Distinguished Professor Emerit of Psychiatry at the University of Pittsburgh School of Medicine, where he chaired that department for 26 years. He also chaired the American Psychiatric Association Task Force for the development of the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders ("DSM 5"), which defines the criteria for the diagnosis and classification of mental disorders. Dr. Kupfer received his M.D. from Yale University in 1965.
- Inderjit Kaul
-
Inderjit Kaul于2024年3月至2025年5月期间担任Bristol Myers Squibb神经精神病学后期临床开发高级副总裁，负责开发和实施CobenfYTM的整体产品开发和临床策略，用于包括精神分裂症（成人和儿科）、双相躁狂症、自闭症谱系障碍、上市后请求和生命周期管理在内的多个适应症。从2020年3月到2024年3月，他在Karuna Therapeutics领导开发了一种用于治疗急性精神分裂症的毒蕈碱激动剂，导致CobenfyTM获得FDA批准。Kaul博士目前是Draig Therapeutics的首席医疗官，在那里他领导了一种AMPA受体阳性变构调节剂的开发，用于治疗重度抑郁症。他的专长涵盖多个治疗领域，重点是神经科学。Kaul博士拥有哈佛大学的医学博士和公共卫生硕士学位。
Inderjit Kaul has served on Board since November 2025. Dr. Kaul has been the Chief Medical Officer at Draig Therapeutics since May 2025, where he leads the development of an AMPA receptor positive allosteric modulator for the treatment of Major Depressive Disorder. Prior to that, Dr. Kaul was the Senior Vice President, Late Stage Clinical Development, Neuropsychiatry at Bristol Myers Squibb from March 2024 until May 2025, where he was responsible for developing and implementing the overall product development and clinical strategy for Cobenfy for multiple indications including schizophrenia (adults and pediatrics), Bipolar Mania, Autism Spectrum Disorder, Post Marketing Requests and life cycle management. He led the development of a mcarinic agonist for the treatment of acute schizophrenia at Karuna Therapeutics from March 2020 until March 2024, resulting in FDA approval of Cobenfy. His expertise spans multiple therapeutic areas with a foc in neuroscience. Dr. Kaul holds an M.D. and an MPH from Harvard University. - Inderjit Kaul于2024年3月至2025年5月期间担任Bristol Myers Squibb神经精神病学后期临床开发高级副总裁，负责开发和实施CobenfYTM的整体产品开发和临床策略，用于包括精神分裂症（成人和儿科）、双相躁狂症、自闭症谱系障碍、上市后请求和生命周期管理在内的多个适应症。从2020年3月到2024年3月，他在Karuna Therapeutics领导开发了一种用于治疗急性精神分裂症的毒蕈碱激动剂，导致CobenfyTM获得FDA批准。Kaul博士目前是Draig Therapeutics的首席医疗官，在那里他领导了一种AMPA受体阳性变构调节剂的开发，用于治疗重度抑郁症。他的专长涵盖多个治疗领域，重点是神经科学。Kaul博士拥有哈佛大学的医学博士和公共卫生硕士学位。
- Inderjit Kaul has served on Board since November 2025. Dr. Kaul has been the Chief Medical Officer at Draig Therapeutics since May 2025, where he leads the development of an AMPA receptor positive allosteric modulator for the treatment of Major Depressive Disorder. Prior to that, Dr. Kaul was the Senior Vice President, Late Stage Clinical Development, Neuropsychiatry at Bristol Myers Squibb from March 2024 until May 2025, where he was responsible for developing and implementing the overall product development and clinical strategy for Cobenfy for multiple indications including schizophrenia (adults and pediatrics), Bipolar Mania, Autism Spectrum Disorder, Post Marketing Requests and life cycle management. He led the development of a mcarinic agonist for the treatment of acute schizophrenia at Karuna Therapeutics from March 2020 until March 2024, resulting in FDA approval of Cobenfy. His expertise spans multiple therapeutic areas with a foc in neuroscience. Dr. Kaul holds an M.D. and an MPH from Harvard University.
- Hans Peter Hasler
-
Hans Peter Hasler，曾一直担任Minerva Neurosciences, Inc.的首席运营官（2008年5月以来），也曾担任Minerva Neurosciences, Inc.的全球神经学执行副总裁、国际业务主管（2007年10月至2008年5月），并管理Minerva Neurosciences, Inc.的国际业务（公司合并以来）。他此前曾担任高级副总裁，以及国际主管（2003年11月至2007年10月）。他曾担任Biogen, Inc.的国际执行副总裁（2003年7月至公司合并），并于2001年8月加入Biogen, Inc，担任执行副总裁，负责商业运营。加入Biogen, Inc之前，他曾任职Wyeth-Ayerst Pharmaceuticals, Inc.（从属于American Home Products, Inc.，AHP），在那里他曾担任高级副总裁、全球战略营销主管（1998年至2001年）。他曾担任Wyeth、AHP的执行委员会的成员，也曾担任商业委员会的主席。1993年至1998年，他曾担任Wyeth-Ayerst Pharmaceuticals公司的多种高级管理职务，包括德国Wyeth-Ayerst Pharmaceuticals的董事总经理，以及Wyeth/AHP的瑞士和欧洲中部东部总经理。加入Wyeth-Ayerst Pharmaceuticals之前，他曾担任Abbott AG的制药部门主管。他是Acino Holding AG、Santhera Pharmaceuticals Holding AG的董事。
Hans Peter Hasler has served on Board since December 2017. Until 2020, Mr. Hasler served as the Chief Executive Officer of Vicari Pharma AG, a privately held company that provided strategic options to non European bio pharma companies hasing late stage assets to the European market. He is also Senior Advisor at SBTech Global Advisory. His prior experience includes Elan Corporation, where he was Chief Operating Officer, and Biogen, Inc., where his positions included Chief Operating Officer, Executive Vice President, Head of Global Neurology and International. Previoly, Mr. Hasler was at Wyeth Pharmaceuticals as Senior Vice President, Chief Marketing Officer and Managing Director of Wyeth Group Germany and General Manager, Wyeth Lederle Switzerland, Atria and ECE. Mr. Hasler has served as Chairman of the Board of HBM Healthcare Investments AG, a SIX Swiss Exchange listed company, since 2009. Mr. Hasler has served as the Chairman of Shield Therapeutics, an AIM listed specialty pharma company, since September 2018, and as a Director of Gain Therapeutics, a Nasdaq listed biotechnology company, since March 2021. Mr. Hasler holds a Federal Swiss Commercial Diploma and a Marketing Manager Certificate from the Swiss Institute of Biness Economy SIB, Zurich, Switzerland. - Hans Peter Hasler，曾一直担任Minerva Neurosciences, Inc.的首席运营官（2008年5月以来），也曾担任Minerva Neurosciences, Inc.的全球神经学执行副总裁、国际业务主管（2007年10月至2008年5月），并管理Minerva Neurosciences, Inc.的国际业务（公司合并以来）。他此前曾担任高级副总裁，以及国际主管（2003年11月至2007年10月）。他曾担任Biogen, Inc.的国际执行副总裁（2003年7月至公司合并），并于2001年8月加入Biogen, Inc，担任执行副总裁，负责商业运营。加入Biogen, Inc之前，他曾任职Wyeth-Ayerst Pharmaceuticals, Inc.（从属于American Home Products, Inc.，AHP），在那里他曾担任高级副总裁、全球战略营销主管（1998年至2001年）。他曾担任Wyeth、AHP的执行委员会的成员，也曾担任商业委员会的主席。1993年至1998年，他曾担任Wyeth-Ayerst Pharmaceuticals公司的多种高级管理职务，包括德国Wyeth-Ayerst Pharmaceuticals的董事总经理，以及Wyeth/AHP的瑞士和欧洲中部东部总经理。加入Wyeth-Ayerst Pharmaceuticals之前，他曾担任Abbott AG的制药部门主管。他是Acino Holding AG、Santhera Pharmaceuticals Holding AG的董事。
- Hans Peter Hasler has served on Board since December 2017. Until 2020, Mr. Hasler served as the Chief Executive Officer of Vicari Pharma AG, a privately held company that provided strategic options to non European bio pharma companies hasing late stage assets to the European market. He is also Senior Advisor at SBTech Global Advisory. His prior experience includes Elan Corporation, where he was Chief Operating Officer, and Biogen, Inc., where his positions included Chief Operating Officer, Executive Vice President, Head of Global Neurology and International. Previoly, Mr. Hasler was at Wyeth Pharmaceuticals as Senior Vice President, Chief Marketing Officer and Managing Director of Wyeth Group Germany and General Manager, Wyeth Lederle Switzerland, Atria and ECE. Mr. Hasler has served as Chairman of the Board of HBM Healthcare Investments AG, a SIX Swiss Exchange listed company, since 2009. Mr. Hasler has served as the Chairman of Shield Therapeutics, an AIM listed specialty pharma company, since September 2018, and as a Director of Gain Therapeutics, a Nasdaq listed biotechnology company, since March 2021. Mr. Hasler holds a Federal Swiss Commercial Diploma and a Marketing Manager Certificate from the Swiss Institute of Biness Economy SIB, Zurich, Switzerland.
- Remy Luthringer
-
Remy Luthringer，博士；自2011年1月起为Minerva Neurosciences, Inc.提供咨询服务，且于2014年3月被指定为Minerva Neurosciences, Inc.的首席执行官兼研发主管。2010年12月起，他一直担任一家风险投资公司 Index Ventures的首席医疗官和合伙人，该公司是Minerva Neurosciences, Inc.的附属机构。在此之前，他从2005年到2010年9月是法国的FORENAP神经科学和神经精神病学研究所的首席执行官兼总裁。他任职于许多私营医疗技术和生命科学公司的董事会。他持有法国路易·巴斯德大学（University Louis Pasteur）的药理学和神经科学博士学位和法国巴黎第六大学（University Paris VI ）功能探索硕士学位，以及法国Rouffach Hosptial的精神科护理学位。他于2014年5月1日成为公司的一员。
Remy Luthringer has provided services to since July 2010, first as a consultant and then as an employee beginning in May 2014. Dr. Luthringer was named President and Chief Executive Officer in November 2014, and served as President until December 2017. He has served on Board since November 2014. Dr. Luthringer previoly served as an advisor to Medicxi Ventures, formerly Index Ventures Life Sciences, and before that served as an advisor to Index Ventures and as Chief Medical Officer to Index Life VI, a biotechnology fund raised by Index Ventures. Dr. Luthringer also serves on the board of directors of a number of private companies. He received his Ph.D. in Pharmacology and Neurosciences from University Louis Pasteur (France). - Remy Luthringer，博士；自2011年1月起为Minerva Neurosciences, Inc.提供咨询服务，且于2014年3月被指定为Minerva Neurosciences, Inc.的首席执行官兼研发主管。2010年12月起，他一直担任一家风险投资公司 Index Ventures的首席医疗官和合伙人，该公司是Minerva Neurosciences, Inc.的附属机构。在此之前，他从2005年到2010年9月是法国的FORENAP神经科学和神经精神病学研究所的首席执行官兼总裁。他任职于许多私营医疗技术和生命科学公司的董事会。他持有法国路易·巴斯德大学（University Louis Pasteur）的药理学和神经科学博士学位和法国巴黎第六大学（University Paris VI ）功能探索硕士学位，以及法国Rouffach Hosptial的精神科护理学位。他于2014年5月1日成为公司的一员。
- Remy Luthringer has provided services to since July 2010, first as a consultant and then as an employee beginning in May 2014. Dr. Luthringer was named President and Chief Executive Officer in November 2014, and served as President until December 2017. He has served on Board since November 2014. Dr. Luthringer previoly served as an advisor to Medicxi Ventures, formerly Index Ventures Life Sciences, and before that served as an advisor to Index Ventures and as Chief Medical Officer to Index Life VI, a biotechnology fund raised by Index Ventures. Dr. Luthringer also serves on the board of directors of a number of private companies. He received his Ph.D. in Pharmacology and Neurosciences from University Louis Pasteur (France).
- Jan van Heek
-
Jan van Heek，本次发行结束后将成为Minerva Neurosciences, Inc.的董事会成员和审计委员会主席。自2009年起，他一直担任一家业务发展咨询公司BioPoint集团的负责人及合伙人，在那里他为生物技术和其他医疗保健公司提供商业战略开发、融资及业务发展方面的建议。在2009年建立BioPoint之前，他在赛诺菲一家制药公司健赞公司（Genzyme Corporation）工作超过18年，最近担任执行副总裁以及首席执行官和高层管理团队的高级顾问。目前，他是一家公开上市的生物制药公司阿玛林公司（Amarin Corporation）的董事会成员。他自2002年起也是一家上市公司ViaCell公司的董事会成员及审计委员会主席，直到它于2007年被出售给珀金埃尔默公司（ Perkin Elmer Corporation）。他持有位于瑞士的圣加仑大学（ St. Gallen University）工商管理硕士学位及斯坦福大学商学院（Stanford Business School）的行政管理学位。
Jan van Heek has served on Board since July 2014. Mr. van Heek advises biotechnology and other healthcare companies in commercial strategy development, financing, and biness development. He was previoly a partner at BioPoint Group, a biotech consulting company. Prior to establishing BioPoint in 2009, Mr. van Heek spent over 18 years at Genzyme Corporation, a Sanofi pharmaceutical company, including as an Executive Vice President and Senior Advisor to the chief executive officer. Mr. van Heek also previoly served as a board member and chairman of the Audit Committee of Amarin Corporation, a publicly traded biopharmaceutical company from 2010 to 2023. He was also a board member and chairman of the Audit Committee of ViaCell Corporation, a public company, from 2002 until it was sold to Perkin Elmer Corporation in 2007. He received an M.B.A. from St. Gallen University in Switzerland and an executive degree from Stanford Biness School. - Jan van Heek，本次发行结束后将成为Minerva Neurosciences, Inc.的董事会成员和审计委员会主席。自2009年起，他一直担任一家业务发展咨询公司BioPoint集团的负责人及合伙人，在那里他为生物技术和其他医疗保健公司提供商业战略开发、融资及业务发展方面的建议。在2009年建立BioPoint之前，他在赛诺菲一家制药公司健赞公司（Genzyme Corporation）工作超过18年，最近担任执行副总裁以及首席执行官和高层管理团队的高级顾问。目前，他是一家公开上市的生物制药公司阿玛林公司（Amarin Corporation）的董事会成员。他自2002年起也是一家上市公司ViaCell公司的董事会成员及审计委员会主席，直到它于2007年被出售给珀金埃尔默公司（ Perkin Elmer Corporation）。他持有位于瑞士的圣加仑大学（ St. Gallen University）工商管理硕士学位及斯坦福大学商学院（Stanford Business School）的行政管理学位。
- Jan van Heek has served on Board since July 2014. Mr. van Heek advises biotechnology and other healthcare companies in commercial strategy development, financing, and biness development. He was previoly a partner at BioPoint Group, a biotech consulting company. Prior to establishing BioPoint in 2009, Mr. van Heek spent over 18 years at Genzyme Corporation, a Sanofi pharmaceutical company, including as an Executive Vice President and Senior Advisor to the chief executive officer. Mr. van Heek also previoly served as a board member and chairman of the Audit Committee of Amarin Corporation, a publicly traded biopharmaceutical company from 2010 to 2023. He was also a board member and chairman of the Audit Committee of ViaCell Corporation, a public company, from 2002 until it was sold to Perkin Elmer Corporation in 2007. He received an M.B.A. from St. Gallen University in Switzerland and an executive degree from Stanford Biness School.
高管简历
中英对照 | 中文 | 英文- Frederick Ahlholm
Frederick Ahlholm，他曾任职Minerva Neurosciences, Inc.（2014年1月以来），最初担任顾问（始于2014年6月）。2014年7月以来，他曾担任Minerva Neurosciences, Inc.的副总裁和首席会计官。加入Minerva公司之前，他曾担任Amarin Corporation（一个商业生物制药公司）的财务副总裁，也曾担任首席会计官（从2010年到2013年）。他是注册会计师，持有圣母大学的工商管理学士学位。
Frederick Ahlholm has provided services to since January 2014, first as a consultant and then as an employee beginning in June 2014. Mr. Ahlholm most recently held the positions of the Company's Vice President and Chief Accounting Officer from July 2014 to October 2021, and Senior Vice President of Finance from May 2015 to October 2021. Prior to joining , Mr. Ahlholm served as Vice President of Finance and Chief Accounting Officer for Amarin Corporation, a commercial stage life science company. Mr. Ahlholm has over 20 years of experience leading the finance organization at publicly traded life science companies. He began his career at Ernst & Young, is a CPA and earned his BA in Biness Administration at the University of Notre Dame.- Frederick Ahlholm，他曾任职Minerva Neurosciences, Inc.（2014年1月以来），最初担任顾问（始于2014年6月）。2014年7月以来，他曾担任Minerva Neurosciences, Inc.的副总裁和首席会计官。加入Minerva公司之前，他曾担任Amarin Corporation（一个商业生物制药公司）的财务副总裁，也曾担任首席会计官（从2010年到2013年）。他是注册会计师，持有圣母大学的工商管理学士学位。
- Frederick Ahlholm has provided services to since January 2014, first as a consultant and then as an employee beginning in June 2014. Mr. Ahlholm most recently held the positions of the Company's Vice President and Chief Accounting Officer from July 2014 to October 2021, and Senior Vice President of Finance from May 2015 to October 2021. Prior to joining , Mr. Ahlholm served as Vice President of Finance and Chief Accounting Officer for Amarin Corporation, a commercial stage life science company. Mr. Ahlholm has over 20 years of experience leading the finance organization at publicly traded life science companies. He began his career at Ernst & Young, is a CPA and earned his BA in Biness Administration at the University of Notre Dame.
- Geoffrey Race
Geoffrey Race，自2010年7月起向Minerva Neurosciences, Inc.提供咨询服务，并于2014年3月被任命为Minerva Neurosciences, Inc.执行副总裁兼首席财务官。从2010年6月至2013年11月，他曾担任Funxional治疗公司（ Funxional Therapeutics Ltd.）的首席执行官和代理首席财务官；该公司是英国一家制药公司，从剑桥大学分离而出。 Funxional Therapeutics最主要的项目于2012年被出售给勃林格殷格翰公司（Boehringer Ingelheim）。在此之前，他从2006年9月至2010年5月曾担任一家抗体开发公司PanGenetics集团的首席财务官；从2010年5月至2011年3月任首席执行官。 PanGenetics110 BV于2009年12月被出售给Abbot Laboratories。2003年8月至2006年4月，他担任一家法国生物制药公司CareX SA的首席执行官，该公司专门从事发现和开发用于治疗代谢性疾病的药物。从2000年12月至2003年5月，他还是从史克必成公司（Smithkline Beecham）分离出来的Adprotech有限公司的首席执行官；从1997年5月至2000年3月也担任一家色谱层析试剂开发公司Bioprocessing有限公司的首席财务官；Bioprocessing后被出售给密理博有限公司（Millipore）。他是英国特许管理会计师公会（ the Institute of Chartered Management Accountants）的会员，并持有英国杜伦大学（ Durham University）商学院的工商管理硕士学位。他于2014年5月1日成为公司的一名员工。
Geoffrey Race has provided services to since July 2010, first as a consultant and then as an employee beginning in May 2014. Mr. Race most recently held the positions of the Company's Executive Vice President and Chief Financial Officer, from May 2014 to October 2021, and Chief Biness Officer from January 2016 to October 2021. Prior to joining , Mr. Race served as the Chief Executive Officer and acting Chief Financial Officer of Funxional Therapeutics Ltd., a clinical stage pharmaceutical company which was spun out of Cambridge University, UK, from June 2010 to November 2013. Mr. Race is currently a member of the board of directors of Huq Indtries Ltd. Mr. Race is also a founder and director of Cyber Indtries Ltd., a UK based private company developing software for building management systems. He was a director of Sensyne Health plc and of F star Therapeutics Ltd. Mr. Race is a Fellow of the Institute of Chartered Management Accountants and earned his M.B.A. from Durham University Biness School (UK).- Geoffrey Race，自2010年7月起向Minerva Neurosciences, Inc.提供咨询服务，并于2014年3月被任命为Minerva Neurosciences, Inc.执行副总裁兼首席财务官。从2010年6月至2013年11月，他曾担任Funxional治疗公司（ Funxional Therapeutics Ltd.）的首席执行官和代理首席财务官；该公司是英国一家制药公司，从剑桥大学分离而出。 Funxional Therapeutics最主要的项目于2012年被出售给勃林格殷格翰公司（Boehringer Ingelheim）。在此之前，他从2006年9月至2010年5月曾担任一家抗体开发公司PanGenetics集团的首席财务官；从2010年5月至2011年3月任首席执行官。 PanGenetics110 BV于2009年12月被出售给Abbot Laboratories。2003年8月至2006年4月，他担任一家法国生物制药公司CareX SA的首席执行官，该公司专门从事发现和开发用于治疗代谢性疾病的药物。从2000年12月至2003年5月，他还是从史克必成公司（Smithkline Beecham）分离出来的Adprotech有限公司的首席执行官；从1997年5月至2000年3月也担任一家色谱层析试剂开发公司Bioprocessing有限公司的首席财务官；Bioprocessing后被出售给密理博有限公司（Millipore）。他是英国特许管理会计师公会（ the Institute of Chartered Management Accountants）的会员，并持有英国杜伦大学（ Durham University）商学院的工商管理硕士学位。他于2014年5月1日成为公司的一名员工。
- Geoffrey Race has provided services to since July 2010, first as a consultant and then as an employee beginning in May 2014. Mr. Race most recently held the positions of the Company's Executive Vice President and Chief Financial Officer, from May 2014 to October 2021, and Chief Biness Officer from January 2016 to October 2021. Prior to joining , Mr. Race served as the Chief Executive Officer and acting Chief Financial Officer of Funxional Therapeutics Ltd., a clinical stage pharmaceutical company which was spun out of Cambridge University, UK, from June 2010 to November 2013. Mr. Race is currently a member of the board of directors of Huq Indtries Ltd. Mr. Race is also a founder and director of Cyber Indtries Ltd., a UK based private company developing software for building management systems. He was a director of Sensyne Health plc and of F star Therapeutics Ltd. Mr. Race is a Fellow of the Institute of Chartered Management Accountants and earned his M.B.A. from Durham University Biness School (UK).
- Remy Luthringer
Remy Luthringer，博士；自2011年1月起为Minerva Neurosciences, Inc.提供咨询服务，且于2014年3月被指定为Minerva Neurosciences, Inc.的首席执行官兼研发主管。2010年12月起，他一直担任一家风险投资公司 Index Ventures的首席医疗官和合伙人，该公司是Minerva Neurosciences, Inc.的附属机构。在此之前，他从2005年到2010年9月是法国的FORENAP神经科学和神经精神病学研究所的首席执行官兼总裁。他任职于许多私营医疗技术和生命科学公司的董事会。他持有法国路易·巴斯德大学（University Louis Pasteur）的药理学和神经科学博士学位和法国巴黎第六大学（University Paris VI ）功能探索硕士学位，以及法国Rouffach Hosptial的精神科护理学位。他于2014年5月1日成为公司的一员。
Remy Luthringer has provided services to since July 2010, first as a consultant and then as an employee beginning in May 2014. Dr. Luthringer was named President and Chief Executive Officer in November 2014, and served as President until December 2017. He has served on Board since November 2014. Dr. Luthringer previoly served as an advisor to Medicxi Ventures, formerly Index Ventures Life Sciences, and before that served as an advisor to Index Ventures and as Chief Medical Officer to Index Life VI, a biotechnology fund raised by Index Ventures. Dr. Luthringer also serves on the board of directors of a number of private companies. He received his Ph.D. in Pharmacology and Neurosciences from University Louis Pasteur (France).- Remy Luthringer，博士；自2011年1月起为Minerva Neurosciences, Inc.提供咨询服务，且于2014年3月被指定为Minerva Neurosciences, Inc.的首席执行官兼研发主管。2010年12月起，他一直担任一家风险投资公司 Index Ventures的首席医疗官和合伙人，该公司是Minerva Neurosciences, Inc.的附属机构。在此之前，他从2005年到2010年9月是法国的FORENAP神经科学和神经精神病学研究所的首席执行官兼总裁。他任职于许多私营医疗技术和生命科学公司的董事会。他持有法国路易·巴斯德大学（University Louis Pasteur）的药理学和神经科学博士学位和法国巴黎第六大学（University Paris VI ）功能探索硕士学位，以及法国Rouffach Hosptial的精神科护理学位。他于2014年5月1日成为公司的一员。
- Remy Luthringer has provided services to since July 2010, first as a consultant and then as an employee beginning in May 2014. Dr. Luthringer was named President and Chief Executive Officer in November 2014, and served as President until December 2017. He has served on Board since November 2014. Dr. Luthringer previoly served as an advisor to Medicxi Ventures, formerly Index Ventures Life Sciences, and before that served as an advisor to Index Ventures and as Chief Medical Officer to Index Life VI, a biotechnology fund raised by Index Ventures. Dr. Luthringer also serves on the board of directors of a number of private companies. He received his Ph.D. in Pharmacology and Neurosciences from University Louis Pasteur (France).